Drug Profile
Research programme: lung cancer therapeutics - Sankyo
Latest Information Update: 27 Nov 2007
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer OncoTherapy Science
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lung cancer
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 24 Sep 2003 Preclinical trials in Lung cancer in Japan (unspecified route)